Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Transfection of embryo fibroblasts by a human ras oncogene does not convert them into tumour cells unless the fibroblasts are established and immortalized before transfection. The embryo fibroblasts become tumorigenic if a second oncogene such as a viral or cellular myc gene or the gene for the polyoma large-T antigen is introduced together with the ras gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16.”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“ras cooperates, however, with certain other oncogenic alterations to transform primary rodent cells (Land et al. 1983; Ruley 1983), including overexpression of c-Myc, dominant negative p53, D-type cyclins, and Cdc25A and -B, and loss of p53, p16, or IRF-1”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“In that setting, dysfunctional telomeres induced a strong cellular senescence phenotype in the emerging lymphomas resulting in potent suppression of lymphomagenesis.”
From Telomeres and telomerase in cancer (2010) · cites this paper as [93]
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Mutation selection and the natural history of cancer
Cairns, J. (1975) · Nature · doi:10.1038/255197a0 · Cited by 1,582
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis
Hayward, W. S., Neel, B. G., & Astrin, S. M. (1981) · Nature · doi:10.1038/290475a0 · Cited by 1,567
Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., & Leder, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7837 · Cited by 1,422
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Self-citationRuley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Self-citationDer, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
Research works printed but not linked: 9
- Berenblum, I. & Shubik, P. Br. J. Cancer 1, 388 (1947).
- Emmelot, P. & Scherer, E. Cancer Res. 37, 1702–1708 (1977).
- Crawford, B. D., Barrett, J. C. & Ts'o, P. O. P. Molec. cell. Biol. 3, 931–945 (1983). · doi:10.1128/mcb.3.5.931
- Murray, M. J. et al. Cell (in the press).
- Aaronson, S. A. & Todaro, G. J. J. Cell Biol. 72, 141–148 (1968).
- Perucho, M., Hanahan, D. & Wigler, M. Cell 22, 309–317 (1980). · DOI · Paper page
- Beard, J. W. in Viral Oncology (ed. Klein, G.) 55–88 (Raven, New York, 1980).
- Adams, J. M., Gerondakis, S., Webb, E., Corcoran, L. & Cory, S. Proc. natn. Acad. Sci. U.S.A. (in the press).
- Gross, L. Oncogenic viruses, 931 (Pergamon, Oxford, 1970).
Cited by
Items 901–1,000 of 1,010
Cohen, K. J., Hanna, J. S., Prescott, J. E., & Dang, C. V. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5527 · Cited by 61
Hesketh, J. E., Campbell, G., Piechaczyk, M., & Blanchard, J. (1994) · Biochemical Journal · doi:10.1042/bj2980143 · Cited by 61
Bignami, M., Rosa, S., Falcone, G., Tatò, F., Katoh, F., & Yamasaki, H. (1988) · Molecular Carcinogenesis · doi:10.1002/mc.2940010113 · Cited by 61
Payne, P. A., Olson, E. N., Hsiau, P., Roberts, R., Perryman, M. B., & Schneider, M. D. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.8956 · Cited by 61
Greatwall promotes cell transformation by hyperactivating AKT in human malignancies
Vera, J., Lartigue, L., Vigneron, S., Gadéa, G., Gire, V., Rio, M. D., Soubeyran, I., Chibon, F., Lorca, T., & Castro, A. (2015) · eLife · doi:10.7554/elife.10115 · Cited by 62
“To this aim, we stably overexpressed pMXs-based constructs encoding wild type (WT), hyperactive kinase (K72M) or kinase dead (G44S) GWL or with empty vector (CT) into MCF10A cells, and we compared their proliferative and transforming capacities to those observed in MCF10A overexpressing the V12Ras oncogene (Figure 1A).”
BackgroundMethodInfluentialThe Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance
Kumari, A., Folk, W. P., & Sakamuro, D. (2017) · Genes · doi:10.3390/genes8060158 · Cited by 61
“The first evidence for MYC as an immortalizing factor came from a classical RAS co-transformation assay using primary rodent fibroblasts as an in vitro cancer model system [39].”
BackgroundMethodInfluentialThe cellular and molecular basis of prostate cancer
Foster, Cornford, Forsyth, Djamgoz, & Ke (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00954.x · Cited by 70
Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
Koskinen, P. J., Ayer, D. E., & Eisenman, R. N. (1995) · PubMed · Cited by 60
Persson, H., Gray, H. E., & Godeau, F. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.11.2903 · Cited by 60
Sklar, M. D., Thompson, E., Welsh, M. J., Liebert, M., Harney, J., Grossman, H. B., Smith, M. J., & Prochownik, E. V. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.7.3699 · Cited by 64
Pfeifer, A. M. A., Mark, G. E., Malan-Shibley, L. B., Graziano, S. L., Amstad, P., & Harris, C. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10075 · Cited by 60
Syndromes of Acute Nonlymphocytic Leukemia
KOEFFLER, H. P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-748 · Cited by 60
Pozzatti, R., McCormick, M., Thompson, M. A., & Khoury, G. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.7.2984 · Cited by 60
Amplification of N-myc in human neuroblastomas
Schwab, M. (1985) · Trends in Genetics · doi:10.1016/0168-9525(85)90103-9 · Cited by 60
Oliff, A. I., Agranovsky, O., McKinney, M. D., Murty, V. V. V. S., & Bauchwitz, R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.10.3306 · Cited by 60
Smith, D. H., & Ziff, E. B. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.9.3882 · Cited by 60
Irons, R., & Stillman, W. S. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.961041239 · Cited by 59
c-Myc-Induced Genomic Instability
Mai, S., & Mushinski, J. F. (2003) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvpathtoxoncol.v22.i3.30 · Cited by 73
“Early studies implicated MYC in cell proliferation (Palmieri et al. 1983), but it was insufficient for cellular transformation unless it cooperated with a second oncogene, RAS, to transform primary embryo fibroblasts (Land et al. 1983, 1986).”
BackgroundGodeau, F., Persson, H., Gray, H. E., & Pardee, A. B. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04684.x · Cited by 59
Laurent‐Puig, P., Olschwang, S., Delattre, O., Validire, P., Melot, T., Mosseri, V., Salmon, R. J., & Thomas, G. D. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490213 · Cited by 59
Bishop, J. M. (1985) · Trends in Genetics · doi:10.1016/0168-9525(85)90094-0 · Cited by 59
Mueller-Lantzsch, N., Lenoir, G., Sauter, M., Takaki, K., Béchet, J., Kuklik-Roos, C., Wunderlich, D. A., & Bornkamm, G. W. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03854.x · Cited by 59
Glenn, G. M., & Ricciardi, R. P. (1985) · Journal of Virology · doi:10.1128/jvi.56.1.66-74.1985 · Cited by 59
Selective requirement for Mediator MED23 in Ras-active lung cancer
Xu, Y., Zhao, M. L., Xia, M. H., Liu, Y., Yan, J., Ji, H., & Wang, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204311109 · Cited by 64
“In contrast to transforming immortalized MEFs, transforming primary MEFs requires multiple cooperating oncogenes (34).”
BackgroundMechanisms of oncogenic cooperation in cancer initiation and metastasis.
Pedraza, L. G. (2006) · PubMed Central · Cited by 95
MIKULSKI, S., Viera, A., Darżynkiewicz, Z., & Shogen, K. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.261 · Cited by 62
“Although the activated ras genes may not be able to induce malignant transformation by themselves, they can be effective as co-inducers of such transformation in cooperation with, e.g., nuclear oncogenes such as c-myc (Land et al., 1983; Weinberg, 1989).”
BackgroundMechanisms for the Initiation and Promotion of Carcinogenesis: A Review and a New Concept
Scott, R. E., Wille, J. J., & Wier, M. L. (1984) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60244-4 · Cited by 58
SV40‐immortalization of rabbit articular chondrocytes: Alteration of differentiated functions
Thenet, S., Benya, P. D., Demignot, S., Feunteun, J., & Adolphe, M. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041500121 · Cited by 65
Deguchi, H., Hamano, H., & Hayashi, Y. (1993) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1993.tb01152.x · Cited by 58
c-myc Reverses neu -induced Transformed Morphology by Transcriptional Repression
Suen, T.-C., & Hung, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.354 · Cited by 58
c-myc Oncogene expression inhibits the initiation of myogenic differentiation
Denis, N., Blanc, S., Leibovitch, M.-P., Nicolaı̈ew, N., Dautry, F., Raymondjean, M., Kruh, J., & Kitzis, A. (1987) · Experimental Cell Research · doi:10.1016/0014-4827(87)90107-8 · Cited by 58
Michalovitz, D., Fischer-Fantuzzi, L., Vesco, C., Pipas, J. M., & Oren, M. (1987) · Journal of Virology · doi:10.1128/jvi.61.8.2648-2654.1987 · Cited by 57
“Neoplastic transformation of nonestablished rodent cells, induced by transfection of nonreplicating plasmids, usually requires the introduction of more than a single oncogene (16, 17, 29, 37).”
BackgroundGenetic Analysis of Adenoviruses
Shenk, T. E., & Williams, J. (1984) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-69549-0_1 · Cited by 58
Malignant conversion of murine squamous papilloma cell lines by transfection with the fos oncogene
Greenhalgh, D. A., & Yuspa, S. H. (1988) · Molecular Carcinogenesis · doi:10.1002/mc.2940010209 · Cited by 58
Germ line transmission of autonomous genetic elements in transgenic mouse strains
Rassoulzadegan, M., Léopold, P., Vailly, J., & Cuzin, F. (1986) · Cell · doi:10.1016/0092-8674(86)90876-7 · Cited by 58
Thomassen, D. G., Gilmer, T. M., La, A., & Jc, B. (1985) · PubMed · Cited by 58
Huggett, A. C., Ellis, P. A., Ford, C. P., Hampton, L. L., Rimoldi, D., & Thorgeirsson, S. S. (1991) · PubMed · Cited by 58
Tsichlis, P. N., Strauss, P., & Lohse, M. A. (1985) · Journal of Virology · doi:10.1128/jvi.56.1.258-267.1985 · Cited by 53
“Transfection of these cells with cloned DNA of myc, polyoma large T antigen (17), or the adenovirus gene coding for the ElA protein (32) renders them susceptible to transformation by ras.”
BackgroundRegulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts
Kole, H. K., Resnick, R. J., Van Doren, M., & Racker, E. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90084-v · Cited by 57
Hellfritsch, J., Kirsch, J., Schneider, M., Fluege, T., Wortmann, M., Frijhoff, J., Dagnell, M., Fey, T., Esposito, I., Kölle, P., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5889 · Cited by 55
“Immortalized MEFs were transformed by lentiviral transduction of the proto-oncogene c-Myc and the oncogene Haras and plated in soft agar (28).”
MethodCooperative Hedgehog-EGFR signaling
Mangelberger, D., Kern, D., Loipetzberger, A., Eberl, M., & Aberger, F. (2011) · Frontiers in bioscience · doi:10.2741/3917 · Cited by 59
“RAS, MYC, BCL2) can fuel cancer growth (1-5), but the restricted druggability of many of those interacting cancer genes has hampered translation of combined targeting to medical cancer therapy.”
Background40 Years of RAS—A Historic Overview
Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 61
“In particular, transfection studies using RAS oncogenes showed that fibroblast immortality is a prerequisite for transformation by the HRAS oncogene [21], and that tumorigenic conversion of primary embryo fibroblasts requires transfection of a separate, cooperating oncogene (MYC or Large T antigen) in addition to the…”
BackgroundEthanol inhibits liver regeneration in rats without reducing transcripts of key protooncogenes
Diehl, A. M., Thorgeirsson, S. S., & Steer, C. J. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90631-a · Cited by 57
Transgenic animals in biomedicine and agriculture: outlook for the future
Wheeler, M. B., Walters, E. M., & Clark, S. G. (2003) · Animal Reproduction Science · doi:10.1016/s0378-4320(03)00168-4 · Cited by 64
“These results suggest additional cellular events are required to realize oncogene-mediated tumor development (Land et al., 1983).”
BackgroundPohjanpelto, P., & Hölttä, E. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5814 · Cited by 61
Thompson, T. C., Timme, T. L., Kadmon, D., Park, S. H., Egawa, S., & Yoshida, K. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940070307 · Cited by 58
Recessive mechanisms of malignancy
Green, A. R. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.176 · Cited by 57
Adenovirus: Transformation and oncogenicity
Bernards, R., & van der Eb, A. J. (1984) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(84)90029-0 · Cited by 57
CYTOGENETICS AND MOLECULAR GENETICS IN MULTIPLE MYELOMA
Feinman, R., Sawyer, J. R., Hardin, J., & Tricot, G. J. K. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70412-3 · Cited by 57
Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones
Sistonen, L., Keski‐Oja, J., Ulmanen, I., Hölttä, E., Wikgren, B.-J., & Alitalo, K. K. (1987) · Experimental Cell Research · doi:10.1016/0014-4827(87)90024-3 · Cited by 57
Srivastava, A., Norris, J. S., Reis, R. J. S., & Goldstein, S. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88987-6 · Cited by 57
Immortalized cells and one oncogene in malignant transformation: old insights on new explanation
Kavsan, V., Iershov, A., & Balynska, O. V. (2011) · BMC Cell Biology · doi:10.1186/1471-2121-12-23 · Cited by 56
“Further, many research groups demonstrated that 2 oncogenes being introduced simultaneously can cooperate in driving normal rodent cells to neoplastic state, in these pairs one of oncogenes induces immortality [2].”
BackgroundSheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
“Because primary MEFs require cooperating oncogenes in addition to mutant RAS to promote transformation (19), we first generated immortalized MEFs that can be transformed by mutant RAS alone (20).”
BackgroundOncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 63
“Instead, combinations of two oncogenes, such as myc and H-ras or E1A and H-ras, led to morphological and functional transformation (22, 23).”
BackgroundMilyavsky, M., Tabach, Y., Shats, I., Erez, N., Cohen, Y., Tang, X., Kalis, M., Kogan, I., Buganim, Y., Goldfinger, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3880 · Cited by 56
“It is also possible that similar transcriptional programs provide the basis for the long-known cooperative effect between pairs of oncogenes in transformation (56, 57).”
BackgroundFischer-Fantuzzi, L., & Vesco, C. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5495-5503.1988 · Cited by 56
“transforming many established cells (2, 13, 14, 21, 51), could induce any colonies in semisolid medium.”
Liao, D. J., Natarajan, G., Deming, S. L., Jamerson, M. H., Johnson, M. D., Chepko, G., & Dickson, R. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203430 · Cited by 56
“…strikingly enhances c-Myc-induced carcinogenesis (Sinn et al., 1987), in line with the in vitro studies showing that cotransfection of cells with tgfa and c-myc e ectively induces transformed phenotype, in contrast to transfection of either gene alone (Amati et al., 1998; Land et al., 1983).”
BackgroundResultRapid intracellular turnover of adenovirus 5 early region 1A proteins
Spindler, K. R., & Berk, A. J. (1984) · Journal of Virology · doi:10.1128/jvi.52.2.706-710.1984 · Cited by 56
Yamashita, K., Adachi, M., Kato, S., Nakagama, H., Ochiai, M., Wakabayashi, K., Sato, S., Nagao, M., & Sugimura, T. (1990) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1990.tb02593.x · Cited by 58
Wilson, R. E., Dooley, T. P., & Hart, I. R. (1989) · PubMed · Cited by 56
Inositol lipids and cell proliferation
Berridge, M. J., Heslop, J. P., Irvine, R. F., & Brown, K. D. (1985) · Biochemical Society Transactions · doi:10.1042/bst0130067 · Cited by 56
Oncogenes, Inositol Lipids and Cellular Proliferation
Berridge, M. J. (1984) · Nature Biotechnology · doi:10.1038/nbt0684-541 · Cited by 68
Cuzin, F. (1984) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(84)90084-8 · Cited by 56
Trosko, J. E., & Chang, C. (2009) · Toxicology · doi:10.1016/j.tox.2009.11.019 · Cited by 61
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
“However, oncogene activation by itself, through either an activating point mutation in the oncogene or mutation/deletion of the aforementioned tumour suppressors, is inadequate for cellular transformation [63] since mechanisms such as apoptosis and senescence pathways are activated [1].”
BackgroundA unified theory for the development of cancer
Spandidos, D. A. (1986) · Bioscience Reports · doi:10.1007/bf01116536 · Cited by 55
“Thus oncogenes cannot be strictly placed into rigid categories ( 34 ) according to the steps in which they might act during carcinogenesis (16).”
BackgroundKortum, R. L., Johnson, H. J., Costanzo, D. L., Volle, D. J., Razidlo, G. L., Fusello, A. M., Shaw, A. S., & Lewis, R. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2202-2214.2006 · Cited by 65
“In mammalian fibroblasts, activated Ras can cause either transformation or irreversible growth arrest, depending on the cellular context and the expression of cooperating oncogenes (11, 39, 59).”
BackgroundLing, C. C., Chen, C. H., & Li, W. X. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90099-x · Cited by 55
Presence of Human Papilloma Virus Type 16 DNA Sequences in Human Nonmelanoma Skin Cancers
Pierceall, W. E., Goldberg, L. H., & Ananthaswamy, H. N. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12491612 · Cited by 56
Sequential protooncogene expression in regenerating kidney following acute renal injury
Cowley, B. D., Chadwick, L. J., Grantham, J. J., & Calvet, J. P. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83194-5 · Cited by 55
Functions of Myc:Max in the Control of Cell Proliferation and Tumorigenesis
Hurlin, P. J., & Dezfouli, S. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)38004-6 · Cited by 62
van Elsas, A., Zerp, S. F., van der Flier, S., Krüse-Wolters, M., Vacca, A., Ruiter, D. J., & Schrier, P. I. (1995) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-78771-3_5 · Cited by 55
“Since it is generally assumed that ras mutations at position 61 activate the protein and lead to transformation (Land et al. 1983) or progression (Fearon and Vogelstein 1990), our finding on the presence of the mutation in the intraepidermal tumor part only is surprising.”
BackgroundB-myb rescues ras-induced premature senescence, which requires its transactivation domain
Masselink, H., Vastenhouw, N. L., & Bernards, R. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00631-0 · Cited by 54
MECHANISMS OF CELL-CYCLE CHECKPOINTS: AT THE CROSSROADS OF CARCINOGENESIS AND DRUG DISCOVERY*
Flatt, P. M., & Pietenpol, J. A. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102335 · Cited by 70
Gaumont-Leclerc, M.-F., Mukhopadhyay, U. K., Goumard, S., & Ferbeyre, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403893200 · Cited by 54
Identification of Sequences Required for Inhibition of Oncogene-mediated Transformation by pp32
Brody, J. R., Kadkol, S. S., Mahmoud, M. A., Rebel, J. M. J., & Pasternack, G. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20053 · Cited by 54
Activated v-myc and v-ras oncogenes do not transform normal human lymphocytes.
Stevenson, M., & Volsky, D. J. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.10.3410 · Cited by 55
The role of c-myc in the proliferation of normal and neoplastic cells
Kelly, K., & Siebenlist, U. K. (1985) · Journal of Clinical Immunology · doi:10.1007/bf00915003 · Cited by 61
“Only certain combinations of oncogenes (e.g., highly activated myc and mutated ras) can effectively transform a cell as assayed by immortalized growth in vitro and tumor formation in nude mice ( 93 ).”
BackgroundStem cell theory of carcinogenesis
Trosko, J. E., & Chang, C. C. (1989) · Toxicology Letters · doi:10.1016/0378-4274(89)90038-6 · Cited by 54
Abnormal signal transduction: A hypothetical model for bipolar affective disorder
Lachman, H. M., & Papolos, D. F. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90031-3 · Cited by 54
Mek1 Phosphorylation Site Mutants Activate Raf-1 in NIH 3T3 Cells
Alessandrini, A., Greulich, H. E., Huang, W., & Erikson, R. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31612 · Cited by 54
Alexander, W. S., Adams, J. M., & Cory, S. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.1.67 · Cited by 54
Oncogenes in human primary hepatic cancer
Gu, J., Li-Fu, H., Yuan-Ching, C., & Da-Fong, W. (1986) · Journal of Cellular Physiology · doi:10.1002/jcp.1041290405 · Cited by 54
Mutant p53 in cell-cell interactions
Pilley, S., Rodriguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 53
“This feature is reminiscent of the oncogene cooperation in the transformation of primary cells, described some 40 yr ago (Land et al. 1983).”
BackgroundPrep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis
Dardaei, L., Longobardi, E., & Blasi, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321200111 · Cited by 55
“Transformation of primary rodent fibroblasts requires at least two oncogenes or one oncogene in the absence of a tumor suppressor gene (20, 37).”
BackgroundIssues associated with residual cell-substrate DNA in viral vaccines
Sheng-Fowler, L., Lewis, A. M., & Peden, K. (2009) · Biologicals · doi:10.1016/j.biologicals.2009.02.015 · Cited by 53
Jäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960516)66:4<470::aid-ijc10>3.0.co;2-c · Cited by 278
Schaffhausen, B. S., & Roberts, T. M. (2008) · Virology · doi:10.1016/j.virol.2008.09.042 · Cited by 62
“Where it is not sufficient, MT canbe complementedbyavarietyof oncogenesgenerally thought toact in the nucleus, such as LT (Land, Parada, and Weinberg, 1983), E1A (Ruley, 1983),myc (Land et al.,1983) and p53 (Utermark et al., 2007), aswell as ST (Moule et al., 2004; O'Shea and Fried, 2005), which…”
BackgroundVolpe, J. P. G. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90179-3 · Cited by 53
Chemical carcinogenesis: a current biological perspective
Farber, E. (1984) · Carcinogenesis · doi:10.1093/carcin/5.1.1 · Cited by 54
Skalnik, D. G., Dorfman, D. M., Perkins, A. S., Jenkins, N. A., Copeland, N. G., & Orkin, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8505 · Cited by 54
Hurlin, P. J., Fry, D. G., Maher, V. M., & McCormick, J. J. (1987) · PubMed · Cited by 53
Harper, J. R., Roop, D. R., & Yuspa, S. H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3144-3149.1986 · Cited by 53
“The data presented in this report, obtained by using keratinocytes derived from epidermal papillomas, suggest that a ras-complementing activity may be involved in the early stages of carcinogenesis and are in agreement with previous studies with mesenchymal tissues (9, 13, 14, 19, 24), as well as studies in which othe…”
ResultBurgess, A. W. (1985) · Immunology Today · doi:10.1016/0167-5699(85)90026-x · Cited by 57
Mapping of functional domains in adenovirus E1A proteins.
Krippl, B., Ferguson, B., Jones, N., Rosenberg, M. J., & Westphal, H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7480 · Cited by 53
Multiple cell-type-specific elements regulate Myc protein stability
Herbst, A., Salghetti, S. E., Kim, S. Y., & Tansey, W. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207492 · Cited by 66
“Consistent with the type of genes that Myc controls, Myc has potent growth-promoting properties, and can drive both ectopic S phase progression (Eilers et al., 1989) and oncogenic transformation (Land et al., 1983).”
BackgroundTipping the Balance: Cdk2 Enables Myc to Suppress Senescence
Hydbring, P., & Larsson, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1383 · Cited by 56
Kobets, T., & Williams, G. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.11.011 · Cited by 54
Yoshioka, N., Inoue, H., Nakanishi, K., Oka, K., Yutsudo, M., Yamashita, A., Hakura, A., & Nojima, H. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.1008-1013.2000 · Cited by 57
“For tumorigenic transformation of primary cells, either a collaboration between two oncogenes such as v-myc and oncogenic ras or a combination of oncogenic ras and loss of function of one or more tumor suppressor genes is required (15, 17, 21, 22, 37).”
BackgroundYu, D., & Thomas‐Tikhonenko, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205244 · Cited by 54
“However, for tumorigenic conversion Myc-overexpressing MEF still require co-activation of Ras (Land et al., 1983).”
Background
Metadata
- Authors
- Land, H., Parada, L. F., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Venue
- Nature
- Published
- 1983-08
- Volume
- 304
- Issue
- 5927
- Pages
- 596-602
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1989009382
- Cited by
- 2,804
- References
- 56
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 22 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 22 · 2019: 36 · 2018: 17 · 2017: 23 · 2016: 24 · 2015: 39 · 2014: 27 · 2013: 30 · 2012: 37
- FWCI
- 96.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- embryonic fibroblasts, oncogene cooperation, oncogenic Ras, MYC gene, polyomavirus large T antigen, cell immortalization, transfection
- MeSH terms
- Animals, Antigens, Viral, Antigens, Viral, Tumor, Cell Line, Cell Transformation, Viral, Cells, Cultured, Fibroblasts, Gene Expression Regulation, Genes, Viral, Genetic Complementation Test, Oncogenes, Phenotype, Polyomavirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.